

Review

Syndecans in wound healing, inflammation and vascular biology

Annika N. Alexopoulou, Hinke A.B. Multhaupt, John R. Couchman*

Division of Biomedical Sciences, Imperial College London, Sir Alexander Fleming Building, Exhibition Road, London SW7 2AZ, UK

Received 17 August 2006; received in revised form 20 October 2006; accepted 23 October 2006

Available online 28 October 2006

Abstract

Syndecans are heparan sulphate proteoglycans consisting of a type I transmembrane core protein modified by heparan sulphate and sometimes chondroitin sulphate chains. They are major proteoglycans of many organs including the vasculature, along with glypicans and matrix proteoglycans. Heparan sulphate chains have potential to interact with a wide array of ligands, including many growth factors, cytokines, chemokines and extracellular matrix molecules relevant to growth regulation in vascular repair, hypoxia, angiogenesis and immune cell function. This is consistent with the phenotypes of syndecan knock-out mice, which while viable and fertile, show deficits in tissue repair. Furthermore, there are potentially important changes in syndecan distribution and function described in a variety of human vascular diseases. The purpose of this review is to describe syndecan structure and function, consider the role of syndecan core proteins in transmembrane signalling and also their roles as co-receptors with other major classes of cell surface molecules. Current debates include potential redundancy between syndecan family members, the significance of multiple heparan sulphate interactions, regulation of the cytoskeleton and cell behaviour and the switch between promoter and inhibitor of important cell functions, resulting from protease-mediated shedding of syndecan ectodomains.

© 2006 Elsevier Ltd. All rights reserved.

Keywords: Syndecans; Heparan sulfate; Vasculature; Wound healing; Inflammation

Contents

1. Introduction	506
2. Syndecan structure and interactions	508
2.1. Syndecan ectodomain	508
2.2. Syndecan transmembrane and cytoplasmic domains	510

Abbreviations: A β , amyloid β protein; AD, Alzheimer's disease; AT-III, antithrombin-III; CAA, cerebral amyloid angiopathy; CS, chondroitin sulphate; EB, embryoid body; ECM, extracellular matrix; EGF, epidermal growth factor; ES cells, embryonic stem cells; FGF, fibroblast growth factor; FGFR, fibroblast growth factor receptor; GAG, glycosaminoglycan chains; GlcA, glucuronic acid; GlcNAc, *N*-acetylglucosamine; GlcNAc-T-I, 1,4-*N*-acetylhexosaminyl transferase; GPI, glycosylphosphatidylinositol; HB-GAM, heparin-binding growth associated molecule; HepII, heparin-binding domain; HS, heparan sulphate; HS6ST2, 6-*O*-sulphotransferase-2; HSPGs, heparan sulphate proteoglycans; HUVECs, human umbilical vein endothelial cells; IdoA, iduronic acid; IL-1 β , interleukin-1 β ; IL-8, interleukin-8; LPS, lipopolysaccharide; MI, myocardial infarction; MMP, matrix metalloproteinase; NDST, *N*-deacetylase/*N*-sulphotransferase; NFTs, neurofibrillary tangles; NMR, nuclear magnetic resonance; NO, nitric oxide; PAI-1, plasminogen activator inhibitor-1; PDGF, platelet derived growth factor; PIP₂, phosphatidylinositol (4,5) biphosphate; PKC, protein kinase C; RFPECs, rat fat pad endothelial cells; SPs, senile plaques; TGF- β , transforming growth factor- β ; TIMP-3, tissue inhibitor of metalloproteinase-3; TNF- α , tumour necrosis factor- α ; TSP-1, thrombospondin-1; VEGF, vascular endothelial growth factor.

* Corresponding author. Tel.: +44 20 7594 3190; fax: +44 20 7594 3100.

E-mail address: j.couchman@imperial.ac.uk (J.R. Couchman).

3.	Syndecans and their functions	511
3.1.	Syndecan-1	511
3.2.	Syndecan-2	511
3.3.	Syndecan-3	511
3.4.	Syndecan-4	512
4.	Syndecans in human vascular disease	512
5.	Vascular alterations in the syndecan-4 null mouse	513
6.	The interaction of heparin with FGFs and FGFRs	514
7.	Syndecan-4 and FGF-2 signalling in endothelial and vascular smooth muscle cells	514
8.	Cutaneous wound healing	516
8.1.	Syndecan expression during wound healing	516
8.2.	Wound healing in syndecan-4 null mice	517
8.3.	Regulation of syndecan expression by TNF- α and TGF- β	517
9.	Syndecan shedding and wound repair	517
9.1.	Syndecan shedding and the proteolytic balance in wound fluids	517
9.2.	Syndecan shedding and FGF-2 mitogenicity	518
10.	Syndecan regulation in vascular injury models	519
11.	Syndecans and inflammation	520
11.1.	Syndecan-1 and leukocyte–endothelial cell interactions	520
11.2.	Syndecans and HIV pathogenesis	522
12.	Discussion	522
12.1.	Proteoglycan redundancy in the vascular system	522
12.2.	Growth factors and ECM molecule interactions	522
12.3.	How much proteoglycan is required?	523
12.4.	What role for the extracellular core protein?	523
	Acknowledgements	523
	References	523

1. Introduction

Syndecans are heparan sulphate proteoglycans (HSPGs) consisting of a core protein modified by heparan sulphate (HS) chains. They represent a major class of HSPGs in the vasculature, along with glypicans and matrix HSPGs. While syndecans are type I membrane proteoglycans, glypicans are bound to the membrane by a glycosylphosphatidylinositol (GPI) anchor and the matrix HSPGs including perlecan, agrin and type XVIII collagen are not membrane bound but are enriched in vascular basement membranes. The glypicans and matrix HSPGs have been the subject of recent reviews (Bezakova & Ruegg, 2003; De Cat & David, 2001; Häcker, Nybakken, & Perrimon, 2005; Iozzo, 2005; Jiang & Couchman, 2003; Song & Filmus, 2002). Syndecans-1, -2 and -4 have been purified from vascular sources (Kojima, Shworak, & Rosenberg, 1992; Mertens, Cassiman, Van den Berghe, Vermeylen, & David, 1992), while syndecan-3 has been purified from neonatal rat brain (Chernousov & Carey, 1993). However, all syndecan family members have been identified in cells of the vasculature (Cizmeci-Smith, Langan, Youkey, Showalter, & Carey, 1997; Fears, Gladson, & Woods, 2006; Ishiguro et al., 2000; Li, Brown, Laham,

Volk, & Simons, 1997). Syndecan expression shows temporal and spatial specificity but virtually all nucleated cells express one or more family members. Syndecan-1 is the major syndecan of epithelial cells including vascular endothelium (Cizmeci-Smith et al., 1997; Elenius et al., 1991; Gallo, Kim, Kokenyesi, Adzick, & Bernfield, 1996; Kojima et al., 1992), syndecan-2 is present mostly in mesenchymal, neuronal and smooth muscle cells (Cizmeci-Smith et al., 1997; Pierce, Lyon, Hampson, Cowling, & Gallagher, 1992), syndecan-3 is the major syndecan of the nervous system (Chernousov & Carey, 1993; Hienola, Tumova, Kuleskiy, & Rauvala, 2006), while syndecan-4 is ubiquitously expressed but at lower levels than the other syndecans (Tkachenko, Rhodes, & Simons, 2005; Yoneda & Couchman, 2003). The four mammalian syndecans are derived from a single ancestral invertebrate syndecan, where a vasculature is either absent or an open system. Indeed, invertebrate syndecan is implicated in the regulation of neural migration and axon guidance (Johnson et al., 2004; Rawson et al., 2005; Rhiner, Gysi, Fröhli, Hengartner, & Hajnal, 2005). Additionally, *Drosophila* syndecan is also detected at cellularisation, while at later stages it is present in the lymph glands and gut epithelium (Bellin et al., 2003; Spring, Paine-Saunders, Hynes, &

Download English Version:

<https://daneshyari.com/en/article/8326546>

Download Persian Version:

<https://daneshyari.com/article/8326546>

[Daneshyari.com](https://daneshyari.com)